Evidence map›Paper›PMID 40485385›Full record

ReviewMedicinal research reviews2025

Progress in Molecular Imprinting-From Inhibition of Enzymatic Activity to Regulation of Cellular Pathways.

Milada Vodova, Jaroslava Bezdekova, Marketa Vaculovicova

Abstract readReview
In one paragraph

Review in Medicinal research reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Milada VodovaDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic.ORCID 0000-0003-2387-5603
Jaroslava BezdekovaDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic.
Marketa VaculovicovaDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic.ORCID 0000-0002-6771-1304

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular imprinting is a very powerful tool in life science. The research areas benefiting from a wide range of capabilities of molecularly imprinted polymeric nanoparticles (nanoMIPs) include sample preparation, extraction, sensing/detection, diagnostics, and drug delivery. Recently, a new member of this family-therapy/control of cellular reactions-has arrived. Within this newest field, so far, the design and synthesis of very selective enzymatic inhibitors/activators have been described. Since enzymes act as catalysts of biochemical reactions, nanoMIPs pose enormous potential in managing biological processes. Furthermore, in recent years, articles focused on influencing cellular pathways by either interaction with cell surface receptors or by inactivation of signal molecules have begun to appear. This strategy opens a new perspective for nanoMIPs application-as selective, inexpensive, and stable therapeutics. However, there are still a lot of questions to be answered and many issues that must be addressed before the practical implementation of nanoMIPs in the therapeutic area. Among the main challenges belong safety, biodegradability, biodistribution, and clearance of nanoMIPs from the organism as well as their reproducible large-scale production in accordance with quality control. This review aims to summarize the progress in nanoMIPs development enabling them to overcome main issues and increasing their competitiveness in the therapeutic area.

Indexed as

Enzyme InhibitorsMolecular ImprintingSignal TransductionAnimalsHumansNanoparticlesPolymersEnzyme InhibitorsPolymersenzymeimprinted polymertherapeutics

Identifiers

PMID40485385
PMCPMC12502893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.